Phase 3 N=217 ArterX Surgical Sealant, A Randomized Prospective Multicenter Trial
Vascular Disease
Primary: Immediate Sealing Evidenced by no Bleeding on Clamp Release. — 65; 101 Treatment sites — p=0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=26 Respiratory Impedance and Obliterative Bronchiolitis
Hematopoietic Stem Cell Transplantation · Obliterative Bronchiolitis
Primary: Airway Distensibility With Lung Inflation After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) — 0.07 1/cmH2O*s
Phase 2 N=75 Study Evaluating SKI-606 (Bosutinib) In Subjects With Breast Cancer
Breast Neoplasms · Neoplasm Metastasis
Primary: Progression-Free Survival (PFS) Rate — 39.6 percentage of participants
N/A N=220 Outcome Study to Evaluate Klaricid XL® (Clarithromycin Modified Release) in Patients With Acute Exacerbation of Chronic Bronchitis
Bronchitis
Primary: St. George's Respiratory Questionnaire (SGRQ) Scores at Baseline and End of Treatment — 69.6; 67.4; 61.0; 64.5 units on a scale
Phase 3 N=805 Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
Irritable Bowel Syndrome With Constipation
Primary: Abdominal Pain and Complete Spontaneous Bowel Movement (APC) Responder, 9 Out of 12 Weeks — 12; 51 participants — p=<0.0001
Phase 3 N=643 Trial of Linaclotide in Patients With Chronic Constipation
Chronic Constipation
Primary: Complete Spontaneous Bowel Movement (CSBM) Overall Responder — 46; 42; 7 participants — p=<0.0001
Phase 2 N=420 Randomized, Double-blind, Dose-range-finding, Phase 2 Study of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
Irritable Bowel Syndrome With Constipation
Primary: Change From Baseline in the Weekly Normalized Complete Spontaneous Bowel Movement (CSBM) Rate During Weeks 1 Through 12 of the Treatment Period — 2.90; 2.49; 3.61; 2.68…
Phase 2 N=21 Study of the Effect of Ivacaftor on Lung Clearance Index in Subjects With Cystic Fibrosis and the G551D Mutation
Cystic Fibrosis
Primary: Absolute Change From Baseline in Lung Clearance Index (LCI) — 0.77; -1.30 ratio — p=0.0004
N/A N=160 Patient's Management Receiving Eplerenone Therapy
Left Ventricular Dysfunction Post Myocardial Infarction
Primary: Systolic Ejection Fraction as a Measure of Left Ventricular Dysfunction at Inclusion for Full Analysis Set (FAS) Population — 41.2 Percentage of EDV
Phase 3 N=803 Trial of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation
Irritable Bowel Syndrome Characterized by Constipation
Primary: Abdominal Pain and Complete Spontaneous Bowel Movement (APC) Responder, 9 Out of 12 Weeks — 20; 49; 375; 356 Participants — p=0.0004
Phase 4 N=372 The Efficacy of Prophylactic Antibiotic Administration During Breast Cancer Surgery in Overweight Patients.
Breast Cancer
Primary: Number of Patients With Body Mass Index (BMI) Over 25 Who Developed Surgical Site Infection (SSI) in Groups Who Received Antibiotic Prophylaxis (Prophylaxis Group) and…
N/A N=207 Study of an Investigational Glucose Meter System
Diabetes
Primary: Percent of Self-Test Fingerstick Blood Glucose Results Within +/- 15mg/dL (<75mg/dL) or Within +/- 20% (>=75mg/dL) of Laboratory Glucose Method — 99.51 percentage of…
Phase 3 N=633 Phase III, Randomized, Double-Blind, Placebo-Controlled, Trial of Linaclotide Administered to Patients With Chronic Constipation
Chronic Constipation
Primary: Complete Spontaneous Bowel Movement (CSBM) Overall Responder — 13; 34; 43; 202 participants — p=0.0012
Phase 1 N=30 Autologous Stem Cells for Cardiac Angiogenesis (FOCUS HF)
Ischemic Cardiomyopathy
Primary: Safety of Autologous-bone-marrow Injections — 1; 1; 0; 1 participants
Phase 3 N=326 Trial of Microplasmin Intravitreal Injection for Non-Surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-007) Trial.
Vitreomacular Adhesion
Primary: Proportion of Subjects With Nonsurgical Resolution of Focal Vitreomacular Adhesion at Day 28 — 25.3; 6.2 percentage of participants — p=<0.001